Celldex Therapeutics reported $-78.68M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
AbbVie USD 695M 1.12B Mar/2026
Agenus USD -10.63M 74.49M Dec/2025
Amgen USD 1.82B 486M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Celldex Therapeutics USD -78.68M 2.63M Mar/2026
Glaxosmithkline GBP 846.06M 1.87B Dec/2025
Nektar Therapeutics USD -36.08M 978K Dec/2025
Northwest Biotherapeutics USD -27.18M 7.81M Sep/2025
Pfizer USD 2.69B 4.34B Mar/2026
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Roche Holding CHF 5.47B 1.76B Dec/2025